Anchor Capital Advisors LLC Sells 1,892 Shares of Pfizer Inc. (NYSE:PFE)

Anchor Capital Advisors LLC lowered its stake in Pfizer Inc. (NYSE:PFE) by 16.3% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 9,704 shares of the biopharmaceutical company’s stock after selling 1,892 shares during the period. Anchor Capital Advisors LLC’s holdings in Pfizer were worth $257,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of PFE. Swedbank AB lifted its position in shares of Pfizer by 0.7% in the third quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock worth $166,284,000 after purchasing an additional 37,636 shares in the last quarter. Financial Advocates Investment Management lifted its position in shares of Pfizer by 5.5% in the third quarter. Financial Advocates Investment Management now owns 44,909 shares of the biopharmaceutical company’s stock worth $1,300,000 after purchasing an additional 2,361 shares in the last quarter. United Asset Strategies Inc. lifted its position in shares of Pfizer by 7.1% in the third quarter. United Asset Strategies Inc. now owns 32,274 shares of the biopharmaceutical company’s stock worth $934,000 after purchasing an additional 2,141 shares in the last quarter. Reston Wealth Management LLC bought a new stake in shares of Pfizer in the third quarter worth $83,000. Finally, Aspen Wealth Strategies LLC lifted its position in shares of Pfizer by 22.0% in the third quarter. Aspen Wealth Strategies LLC now owns 10,207 shares of the biopharmaceutical company’s stock worth $295,000 after purchasing an additional 1,843 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of the firm’s stock in a transaction that occurred on Thursday, February 13th. The shares were acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the completion of the purchase, the director now owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. The trade was a 235.84 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Price Performance

NYSE:PFE opened at $26.43 on Friday. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54. The company has a market cap of $149.78 billion, a P/E ratio of 18.74, a P/E/G ratio of 0.64 and a beta of 0.64. The firm’s fifty day moving average price is $26.35 and its two-hundred day moving average price is $27.34. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. During the same period in the prior year, the company posted $0.10 earnings per share. Pfizer’s revenue was up 24.7% compared to the same quarter last year. Equities analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 annualized dividend and a dividend yield of 6.51%. Pfizer’s dividend payout ratio is 121.99%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Wolfe Research assumed coverage on shares of Pfizer in a report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. Guggenheim restated a “buy” rating and set a $33.00 target price on shares of Pfizer in a report on Monday, February 10th. Citigroup lowered their target price on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Finally, Truist Financial lowered their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, December 18th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.